View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 05, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	URGN
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Security Exchange Name	NASDAQ
Entity Registrant Name	UROGEN PHARMA LTD.
Entity Central Index Key	0001668243
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Ordinary Shares Outstanding		22,023,799
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park Drive
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 36,350	$ 49,688
Marketable securities	88,773	97,389
Restricted cash	1,224	523
Accounts receivable	402
Inventory	1,125
Prepaid expenses and other current assets	2,069	1,034
TOTAL CURRENT ASSETS	129,943	148,634
NON-CURRENT ASSETS
Property and equipment, net	1,401	977
Restricted deposit	223	223
Right of use asset	3,011	3,735
Marketable securities	26,499	48,555
Other non-current assets		264
TOTAL ASSETS	161,077	202,388
CURRENT LIABILITIES:
Accounts payable and accrued expenses	9,203	11,186
Employee related accrued expenses	5,744	6,711
Other current liabilities	1,476	1,585
TOTAL CURRENT LIABILITIES	16,423	19,482
NON-CURRENT LIABILITIES:
Long-term lease liability	1,994	2,604
TOTAL LIABILITIES	18,417	22,086
COMMITMENTS AND CONTINGENCIES (Note 14)
SHAREHOLDERS’ EQUITY:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at June 30, 2020 and December 31, 2019; 22,001,296 and 21,026,184 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	60	57
Additional paid-in capital	438,999	407,986
Accumulated deficit	(297,159)	(228,017)
Accumulated other comprehensive income	760	276
TOTAL SHAREHOLDERS’ EQUITY	142,660	180,302
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 161,077	$ 202,388

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (unaudited) - ₪ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Ordinary shares, par value	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, issued	22,001,296	21,026,184
Ordinary shares, outstanding	22,001,296	21,026,184

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
REVENUES	$ 372	$ 18	$ 372	$ 18
COST OF REVENUES	48		48
GROSS PROFIT	324	18	324	18
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES	8,106	9,996	24,694	19,722
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	24,018	13,775	45,991	26,482
OPERATING LOSS	(31,800)	(23,753)	(70,361)	(46,186)
INTEREST AND OTHER INCOME, NET	451	1,276	1,219	2,265
NET LOSS	(31,349)	(22,477)	(69,142)	(43,921)
STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS	(31,349)	(22,477)	(69,142)	(43,921)
OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES	449	281	484	281
COMPREHENSIVE LOSS	$ (30,900)	$ (22,196)	$ (68,658)	$ (43,640)
NET LOSS PER ORDINARY SHARE BASIC AND DILUTED	$ (1.44)	$ (1.08)	$ (3.22)	$ (2.19)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE	21,753,001	20,833,671	21,454,341	20,095,174

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income
Balance at Dec. 31, 2018	$ 90,094	$ 44	$ 212,921	$ (122,871)
Balance,Share at Dec. 31, 2018		16,214,883
Exercise of options into ordinary shares	2,219	$ 2	2,217
Exercise of options into ordinary shares, shares		427,315
Share-based compensation	14,659		14,659
Issuance of ordinary shares in public offering, net of issuance expenses	161,447	$ 11	161,436
Issuance of ordinary shares in public offering, net of issuance expenses, shares		4,207,317
Other comprehensive income	281				$ 281
Net loss	(43,921)			(43,921)
Balance at Jun. 30, 2019	224,779	$ 57	391,233	(166,792)	281
Balance,Share at Jun. 30, 2019		20,849,515
Balance at Mar. 31, 2019	239,591	$ 56	383,850	(144,315)
Balance,Share at Mar. 31, 2019		20,758,348
Exercise of options into ordinary shares	172	$ 1	171
Exercise of options into ordinary shares, shares		91,167
Share-based compensation	7,212		7,212
Other comprehensive income	281				281
Net loss	(22,477)			(22,477)
Balance at Jun. 30, 2019	224,779	$ 57	391,233	(166,792)	281
Balance,Share at Jun. 30, 2019		20,849,515
Balance at Dec. 31, 2019	180,302	$ 57	407,986	(228,017)	276
Balance,Share at Dec. 31, 2019		21,026,184
Exercise of options into ordinary shares	503	$ 1	502
Exercise of options into ordinary shares, shares		275,112
Share-based compensation	14,736		14,736
Issuance of ordinary shares in public offering, net of issuance expenses	15,777	$ 2	15,775
Issuance of ordinary shares in public offering, net of issuance expenses, shares		700,000
Other comprehensive income	484				484
Net loss	(69,142)			(69,142)
Balance at Jun. 30, 2020	142,660	$ 60	438,999	(297,159)	760
Balance,Share at Jun. 30, 2020		22,001,296
Balance at Mar. 31, 2020	150,454	$ 58	415,895	(265,810)	311
Balance,Share at Mar. 31, 2020		21,212,940
Exercise of options into ordinary shares	210		210
Exercise of options into ordinary shares, shares		88,356
Share-based compensation	7,119		7,119
Issuance of ordinary shares in public offering, net of issuance expenses	15,777	$ 2	15,775
Issuance of ordinary shares in public offering, net of issuance expenses, shares		700,000
Other comprehensive income	449				449
Net loss	(31,349)			(31,349)
Balance at Jun. 30, 2020	$ 142,660	$ 60	$ 438,999	$ (297,159)	$ 760
Balance,Share at Jun. 30, 2020		22,001,296

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (69,142)	$ (43,921)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	178	123
Amortization/Accretion on marketable securities	234	(167)
Stock-based compensation	14,736	14,659
Amortization of right of use asset	753	491
Lease liability	(748)	(374)
Changes in operating assets and liabilities:
Increase in inventory	(1,125)
Increase in accounts receivable	(402)
Increase in prepaid expenses and other current assets	(1,035)	(1,082)
Decrease in accounts payable and accrued expenses	(2,046)	(999)
Decrease in employee related accrued expenses	(967)	(1,219)
Net cash used in operating activities	(59,564)	(32,489)
CASH FLOWS FROM INVESTING ACTIVITIES:
Change in restricted deposit		(4)
Purchase of marketable securities	(29,688)	(142,142)
Maturities of marketable securities	60,610
Purchases of property and equipment	(383)	(84)
Net cash provided by (used in) investing activities	30,539	(142,230)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of options into ordinary shares	503	2,217
Issuance of ordinary shares, net of issuance expenses	15,885	161,662
Net cash provided by financing activities	16,388	163,879
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(12,637)	(10,840)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD	50,211	101,571
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD	37,574	90,731
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash purchase of property and equipment	219
Non-cash new lease liabilities	29
Non-cash issuance cost	$ 32
Exercise of options		$ 2

Business and Nature of Operations

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Business and Nature of Operations

NOTE 1-BUSINESS AND NATURE OF OPERATIONS

Nature of Operations

UroGen Pharma Ltd. is an Israeli company incorporated in April 2004 (“UPL”).

UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in October 2015 and began operating in February 2016 (“UPI”).

UPL and UPI (together the “Company”) is a biopharmaceutical company focused on developing and commercializing novel therapies designed to change the standard of care for urological pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, preparing for the commercial launch of our first commercial product, Jelmyto (mitomycin), formerly known as UGN-101, and our product candidate UGN-102, and raising capital to support and expand these activities.

On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto (mitomycin), for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“LG-UTUC”). . Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.

Basis of Presentation

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation

NOTE 2-BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (“SEC”) on March 2, 2020.

The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.

The Company has experienced net losses since its inception and has an accumulated deficit of $297.2 million and $228.0 million as of June 30, 2020 and December 31, 2019, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it continues its commercial launch of Jelmyto, and expands its portfolio and engages in further research and development activities, particularly conducting nonclinical studies and clinical trials.

The success of the Company depends on its ability to develop its technologies to the point of U.S. Food and Drug Administration (“FDA”) approval and subsequent revenue generation and, the Company must raise enough capital to finance these efforts. Based on management’s cash flow projections, the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. However, in the future, the Company may need to raise additional capital to finance the continued operating and capital requirements of the Company. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. If the Company cannot obtain adequate working capital, it may be forced to reevaluate its planned business operations.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 3-SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation and measurement of revenue.

Functional Currency

The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar.

Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as “finance (income) expenses.”

Cash and Cash Equivalents; Marketable Securities

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value.

Cash and cash equivalents and marketable securities totaled $151.6 million as of June 30, 2020. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, “Investments — Debt and Equity Securities”. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses are recorded as a component of interest and other income (expense), net. The cost of securities sold is based on the specific-identification method.

Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.

The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.

Income Taxes

The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which we operate. Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.

The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained upon examination by the taxing authorities based on the technical merits of the position. If this threshold is met, the second step is to measure the tax benefit as the largest amount that is more likely than not of being realized upon ultimate settlement. As of June 30, 2020, and December 31, 2019, the Company had not accrued a provision for uncertain tax positions. See Note 14 for further discussion related to income taxes.

Inventory

We capitalize inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product Jelmyto, the Company commenced capitalization of inventory at the receipt of FDA approval.

The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.

Property and Equipment

Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Property and equipment are depreciated over the following useful lives (in years):

	Useful Lives
Computers and software		3
Laboratory equipment	3-6.5
Furniture	5-16.5
Manufacturing equipment		2

Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.

Leases

The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.

The Company accounts for leases in accordance with ASC Topic 842, “Leases”. The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the condensed consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the condensed consolidated balance sheets.

Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments.

The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option.

Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The Company has lease agreements with lease and non-lease components. We applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”).

ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.

Revenues

Product sales from our product Jelmyto are recognized as revenue under ASC 606 at the point in time that control of the product has been transferred to the customer, generally at the point the product has been delivered to the end consumer. All product sales of Jelmyto are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. Net revenues recognized include management’s estimate of returns, consideration paid to the customer, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340b drug pricing programs, Medicaid drug rebate programs, and the Company’s copay assistance program, which are estimated based on industry benchmarking studies as well as the Company’s historical experience.

The Company also derives revenues from its license and supply agreement (the “Allergan Agreement”) with Allergan Pharmaceuticals International Limited (“Allergan”), a wholly owned subsidiary of Allergan plc. Under the Allergan Agreement, the Company granted Allergan an exclusive license to develop, commercialize, and otherwise exploit products that contain reverse thermal hydrogel (“RTGel”) and agreed to supply Allergan with pre-clinical and clinical quantities of the RTGel product, also referred to as the RTGelvials. The Allergan Agreement contains up-front license fees, future supply fees, development, regulatory, and sales-based milestone payments, and sales-based royalty payments.

Research and Development Expenses

Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.

Selling General and Administrative Expenses

Selling, general and administrative expenses consist primarily of personnel costs (including share-based compensation related to directors, executives, finance, commercial, medical affairs, business development, investor relations and human resources functions). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.

Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of our ordinary shares on the grant date. The Company accounts for forfeitures as they occur according to the FASB’s Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting.

The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.

Net Loss per Ordinary Share

Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive.

For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.

Recently Adopted Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 requires the Company to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the Company’s current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the prior other-than-temporary impairment model.

The Company applied the modified retrospective transition method as of the date of initial application, January 1, 2020, or the Transition Date. As of June 30, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. Similarly, the Company estimates minimal current expected credit losses on trade receivables, and has not recognized any allowance for doubtful accounts in the period

Other Financial Information

6 Months Ended

Jun. 30, 2020

Other Financial Information [Abstract]

Other Financial Information

NOTE 4-OTHER FINANCIAL INFORMATION

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020		December 31, 2019
Accounts payable	$	4,598	$	4,694
Accrued clinical expenses		409		399
Accrued research and development costs		1,358		2,644
Accrued selling, general and administrative expenses		2,240		2,767
Accrued other expense		598		682
Total accounts payable and accrued expenses	$	9,203	$	11,186

Interest and Other (Income) Expenses, Net

Interest and other (income) expenses consisted of the following as of June 30, 2020 and 2019 (in thousands):

	Six Months Ended June 30,
	2020			2019
Interest income	$	(1,331	)	$	(2,353	)
Other finance expenses		112			88
Total finance income	$	(1,219	)	$	(2,265	)

Inventories

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

NOTE 5-INVENTORIES

Inventories consist of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020		December 31, 2019
Raw materials	$	893		—
Finished goods		232		—
	$	1,125	$	—

Fair Value Measurements

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

NOTE 6-FAIR VALUE MEASUREMENTS

The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

Level 1:

Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2:

Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3:

Unobservable inputs that reflect the reporting entity’s own assumptions.

The carrying amounts of the Company’s other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these instruments. No transfers between levels have occurred during the periods presented.

Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of June 30, 2020 are as follows (in thousands):

			Fair Value Measurements Using
			Quoted Prices		Significant
			in Active		Other
	Balance as of		Markets for		Observable
	June 30,		Identical Assets		Inputs
	2020		(Level 1)		(Level 2)
Marketable securities:
US government	$	47,686	$	47,686	$	—
Corporate bonds		44,460		—		44,460
Commercial paper		20,677		—		20,677
Money market funds⁽¹⁾		20,959		20,959		—
Certificates of deposit		2,448		—		2,448
	$	136,230	$	68,645	$	67,585

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands):

			Fair Value Measurements Using
			Quoted Prices		Significant
			in Active		Other
	Balance as of		Markets for		Observable
	December 31,		Identical Assets		Inputs
	2019		(Level 1)		(Level 2)
Marketable securities:
US government	$	66,094	$	66,094	$	—
Corporate bonds		68,084		—		68,084
Commercial paper		7,658		—		7,658
Money market funds⁽¹⁾		16,998		16,998		—
Certificates of deposit		4,108		—		4,108
	$	162,942	$	83,092	$	79,850

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

The Company’s marketable securities are valued based on publicly available quoted market prices for identical securities as of June 30, 2020 and December 31, 2019.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Marketable Securities

NOTE 7-MARKETABLE SECURITIES

The following table summarizes the Company’s marketable securities as of June 30, 2020 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses		Fair Value
Marketable securities:
US government	$	47,152	$	534	$	—	$	47,686
Corporate bonds		44,237		223		—		44,460
Commercial paper		20,676		1		—		20,677
Money market funds⁽¹⁾		20,959		—		—		20,959
Certificates of deposit		2,446		2		—		2,448
	$	135,470	$	760	$	—	$	136,230

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of June 30, 2020 includes $0.5 million of accrued interest receivable. As of June 30, 2020, marketable securities were in a net unrealized gain position of $0.8 million. Unrealized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss.

As of June 30, 2020, the aggregate fair value of marketable securities held by the Company in an unrealized loss position was $17.6 million which consisted of 10 securities. The unrealized loss was primarily caused by recent impacts to the automotive and financial services industries, as well as decreases in the credit ratings of two names in the portfolio. However, the Company does not expect to settle the debentures at a price less than the amortized cost basis of the investment (that is, the Company expects to recover the entire amortized cost basis of the security). Per the Company’s general investment strategy, the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of the amortized cost basis. As of June 30, 2020, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period.

The Company’s marketable securities as of June 30, 2020 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands):

	June 30, 2020		December 31, 2019
Maturities within one year	$	109,732	$	114,386
Maturities after one year through three years		26,498		48,556
	$	136,230	$	162,942

Property and Equipment

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Property and Equipment

NOTE 8-PROPERTY AND EQUIPMENT

Property and equipment, consists of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020			December 31, 2019
Laboratory equipment	$	307		$	259
Computer equipment and software		855			416
Furniture		597			544
Leasehold improvements		589			530
Manufacturing equipment		226			226
		2,574			1,975
Less: accumulated depreciation and amortization		(1,173	)		(998	)
Property and equipment, net	$	1,401		$	977

Depreciation and amortization expenses were $0.1 million and $0.2 million and $0.1 million and $0.1 million, for the three and six months ended June 30, 2020 and 2019, respectively.

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

NOTE 9-LEASES

Operating Leases

The Company has the following office and laboratory facility leases:

•

In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.

•

In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminates in February 2021. The Company’s remaining contractual obligation under this lease is approximately $0.5 million as of June 30, 2020.

•

In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company’s remaining contractual obligation under this lease is approximately $1.1 million as of June 30, 2020. In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises the end of November 2019. The remaining rental payments to be received over the lease term is approximately $0.8 million as of June 30, 2020. The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial.

•

In November 2019, UroGen Pharma Inc. entered into a new lease agreement for an office in Princeton, NJ, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company’s remaining contractual obligation under this lease is approximately $1.4 million as of June 30, 2020.

In addition, the Company has other operating office equipment and vehicle leases. The Company’s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company’s leases do not contain any residual value guarantees or material restrictive covenants. The Company’s leases expire at various dates from 2021 through 2023, with varying renewal and termination options.

The components of lease cost for the three and six months ended June 30, 2020 were as follows (in thousands):

	Three Months Ended June 30, 2020			Six Months Ended June 30, 2020
Operating lease cost	$	428		$	858
Sublease income	$	(56	)	$	(112	)
Variable lease cost		30			86
	$	402		$	832

The amounts recognized as of June 30, 2020 were as follows (in thousands):

	June 30, 2020
Right of use asset	$	3,011
Long-term lease liability		1,994
Other current liabilities		1,476

As of June 30, 2020, no impairment losses have been recognized to date.

Supplemental information related to leases for the periods reported is as follows (in thousands):

	Six Months Ended June 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		849
Right-of-use assets obtained in exchange for new operating lease liabilities		90
Weighted-average remaining lease term of operating leases	2.55 years
Weighted-average discount rate of operating leases	5.45%

Subleases

As of June 30, 2020 undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands):

	Operating Leases
Years ending December 31,
Remainder of 2020	$	61
2021		235
2022		243
2023		251
2024		49
2025 and thereafter	—
	$	839

Sublease income is recognized net within operating expenses. Sublease income for the three and six months ended June 30, 2020 was as follows (in thousands):

		Three Months Ended June 30, 2020				Six Months Ended June 30, 2020
Sublease income from fixed lease payments		$	56			$	112

Revenue from Product Sales

6 Months Ended

Jun. 30, 2020

Revenue From Contract With Customer [Abstract]

Revenue from Product Sales

NOTE 10-REVENUE FROM PRODUCT SALES

Net product sales consist of the following for the three and six months ended June 30, 2020 (in thousands):

		Three Months Ended June 30, 2020				Six Months Ended June 30, 2020
Jelmyto		$	372			$	372

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

License and Collaboration Agreements

6 Months Ended

Jun. 30, 2020

Liscense Agreement [Abstract]

License and Collaboration Agreements

NOTE 11-LICENSE AND COLLABORATION AGREEMENTS

Allergan Agreement

In October 2016, the Company entered into the Allergan Agreement and granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX^®), alone or in combination with certain other active ingredients, referred to as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, the Company granted Allergan a non-exclusive, worldwide license to use certain of the Company’s trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.

Under the Allergan Agreement, Allergan is solely responsible for costs and development of the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide, as well as worldwide commercialization of the Licensed Products after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries.

The Company will supply Allergan with certain quantities of RTGel for development of Licensed Products through Phase 2 clinical trials using BOTOX together with RTGel in patients with overactive bladder, at Allergan’s request and expense. Allergan has the right to reduce the next milestone payment if there is a material supply failure from the Company. Prior to completion of the first Phase 2 clinical trial, Allergan has the right to request that the Company transfers to Allergan our manufacturing process for RTGel and Allergan will assume the responsibility to manufacture RTGel and Licensed Product for its own development and commercialization activities.

Further, the Company is eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones. As of June 30, 2020, since inception of the Allergan Agreement the Company has received a total of $25.0 million in milestone payments from Allergan. Allergan will pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain RTGel-related third-party intellectual properties.

Under the Allergan Agreement, Allergan granted the Company a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of RTGel for the research, development, manufacture and commercialization of any product containing RTGel and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications.

The Company plans to continue to research, develop and commercialize other products combining RTGel with other active ingredients, except that there are certain restrictions with respect to the overactive bladder and neurogenic detrusor overactivity indications. Subject to provisions called out in the Allergan Agreement, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice. In addition, either party may terminate the Allergan Agreement for various reasons.

Agenus Agreement

In November 2019, the Company entered into a license agreement with Agenus Inc, pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus’s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus’ anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade non-muscle invasive bladder cancer.

Pursuant to the license Agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials.

Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-bycountry basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days’ written notice to Agenus. Either party may terminate the license agreement upon 60 days’ notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company’s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party.

As of June 30, 2020, since inception of the Agenus Agreement, the Company has paid a total of $10.0 million in milestone payments, which was recognized in acquired in-process research and development expenses during the three months ended December 31, 2019.

Shareholders' Equity

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Shareholders' Equity

NOTE 12-SHAREHOLDERS’ EQUITY

The Company had 100.0 million ordinary shares authorized for issuance as of June 30, 2020 and December 31, 2019, respectively. The Company had 22.0 million and 21.0 million ordinary shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors (the “Board”). Since its inception, the Board has not declared any dividends.

In January 2019, the Company completed an underwritten public offering of 4,207,317 of its ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $41.00 per share. The net proceeds to the Company from the offering were approximately $161.4 million, after deducting the underwriting discounts and commissions and payment of other offering expenses.

In December 2019, the Company entered into a sales agreement (the “ATM Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may from time to time offer and sell the Company’s ordinary shares having an aggregate offering price of up to $100.0 million to or through Cowen, acting as sales agent or principal. During the second quarter of 2020, the Company sold 700,000 ordinary shares under the ATM Sales Agreement, for gross proceeds of approximately $16.6 million. The net proceeds to the Company after deducting sales commissions to Cowen and other issuance expenses were approximately $15.8 million. The remaining capacity under the ATM Sales Agreement is approximately $83.4 million.

Share-Based Compensation

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

NOTE 13-SHARE-BASED COMPENSATION

In October 2010, the Board approved a share option plan (the “Plan”) for grants to Company employees, consultants, directors, and other service providers.

The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Section 102 of the Israeli Income Tax Ordinance (“Section 102”). The option grants are subject to the track chosen by the Company, either the “regular income” track or the “capital gains” track, as set out in Section 102. The Company registered the Plan under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section 102, the Company is not allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plan, including amounts recorded as salary benefits in the Company’s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the Plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.

Certain management and professional level employees typically receive options and restricted stock units, or RSU, grants upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board and any new, future directors may receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company’s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share on the date of grant.

The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in equal quarterly amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in equal quarterly amounts for the two years following the one-year anniversary of the grant date.

The expected volatility is based on a mix of the Company’s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees’ exercise behavior, and for non-employees, and directors using the contractual term.

In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants.

The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by the Board. The maximum number of ordinary shares that may be issued upon the exercise of stock options under the 2017 Plan is 5,600,000. On January 1, 2018, the share reserve increased by 250,167 to 1,650,167. On October 12, 2018, the Company increased the amount of registered ordinary shares of the Company’s 2017 Plan by 1,900,000 to 3,550,167.

On January 3, 2019, the Company appointed Elizabeth Barrett as its President and Chief Executive Officer. In connection with Ms. Barrett’s employment, she was granted 277,432 options to purchase the Company’s ordinary shares, at an exercise price of $47.57, as well as 317,065 RSUs, with a combined grant-date fair value of $24.1 million.

In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the “Inducement Plan”). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM 5635-1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company. Under the Inducement Plan, an “Award” is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan.

In June 2019, as part of the Company’s Annual Meeting of Shareholders, the Company’s Board of Directors approved grants of 70,000 options to its non-employee directors. Each then current non-employee director, including the Chairman of the Board, received a grant of 10,000 options. Each option is exercisable into one ordinary share of the Company’s stock at an exercise price of $34.83 per share. The options vest quarterly over one year and expire 10 years from grant date. The grant date fair value of these options was approximately $1.9 million.

In December 2019, the Company’s board of directors approved a modification of options and RSU's for a consultant. The Company recorded an expense of $0.9 million under general and administrative expenses with respect to options' modification. No compensation expense was taken in relation to the RSUs modification because the award vests upon a future performance condition that is not currently probable of occurring.

In June 2020, the Company’s Board of Directors granted an aggregate of 70,000 options to its non-employee directors. Each non-employee director, including the Chairman of the Board, received a grant of 10,000 options. Each option is exercisable into one ordinary share of the Company’s stock at an exercise price of $28.24 per share. The options vest quarterly over one year and expire 10 years from the grant date. The grant date fair value of these options was approximately $1.5 million.

The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands):

	For the Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Research and development expenses	$	1,570	$	1,972		3,513		4,310
Selling, general and administrative expenses		5,549		5,240		11,223		10,349
	$	7,119	$	7,212	$	14,736	$	14,659

The total unrecognized compensation cost of options and RSUs at June 30, 2020 is $42.3 million with a weighted average recognition period of 1.82 years.

Income Taxes

6 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 14-INCOME TAXES

UroGen Pharma Ltd. is taxed under Israeli tax laws. As of June 30, 2020, the Company continues to maintain a full valuation allowance against deferred tax assets for all jurisdictions. In evaluating the need for a valuation allowance, the Company considers all sources of taxable income available to realize the deferred tax asset, including the future reversal of existing temporary differences, forecasts of future taxable income, and tax planning strategies. The Company has cumulative global pretax accounting losses for the years ended 2019, 2018 and 2017, and for the six months ended June 30, 2020. The Company will continue to assess the extent to which its deferred tax assets may be realized in the future and will adjust the valuation allowance as needed.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Related Parties

6 Months Ended

Jun. 30, 2020

Related Parties

NOTE 15-RELATED PARTIES

There were no related party transactions for the six months ended June 30, 2020 or the six months ended June 30, 2019 .

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 16-COMMITMENTS AND CONTINGENCIES

In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of June 30, 2020 and December 31, 2019. The Company does not anticipate recognizing any significant losses relating to these arrangements.

Grants from the Israeli Innovation Authority in Israel (“IIA”)

The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA participation in the funding of the Company’s operations was as part of the Israeli Ministry of Industry and Commerce Director General Directive 8.2 by grants provided to Granot Ventures, a government supported technology incubator. Since 2008, the funding was provided directly to Company.

On January 12, 2020, the IIA Office of Chief Scientist approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement.

Leases

See Note 9 for further discussion regarding lease commitments.

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

NOTE 17-SUBSEQUENT EVENTS

The Company has evaluated and determined there were no subsequent events requiring disclosure through August 10, 2020.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation

The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.

Use of Estimates

Functional Currency

Cash and Cash Equivalents; Marketable Securities

Concentration of Credit Risk

Income Taxes

Inventory

Property and Equipment

Property and equipment are depreciated over the following useful lives (in years):

	Useful Lives
Computers and software		3
Laboratory equipment	3-6.5
Furniture	5-16.5
Manufacturing equipment		2

Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.

Leases

The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases.

Revenues

Research and Development Expenses

Selling General and Administrative Expenses

Share-Based Compensation

Net Loss per Ordinary Share

For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.

Recently Adopted Accounting Pronouncements

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Property and Equipment Useful Lives

Property and equipment are depreciated over the following useful lives (in years):

	Useful Lives
Computers and software		3
Laboratory equipment	3-6.5
Furniture	5-16.5
Manufacturing equipment		2

Other Financial Information (Tables)

6 Months Ended

Jun. 30, 2020

Other Financial Information [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020		December 31, 2019
Accounts payable	$	4,598	$	4,694
Accrued clinical expenses		409		399
Accrued research and development costs		1,358		2,644
Accrued selling, general and administrative expenses		2,240		2,767
Accrued other expense		598		682
Total accounts payable and accrued expenses	$	9,203	$	11,186

Schedule of Interest and Other (Income) Expenses

Interest and other (income) expenses consisted of the following as of June 30, 2020 and 2019 (in thousands):

	Six Months Ended June 30,
	2020			2019
Interest income	$	(1,331	)	$	(2,353	)
Other finance expenses		112			88
Total finance income	$	(1,219	)	$	(2,265	)

Inventories (Tables)

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories consist of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020		December 31, 2019
Raw materials	$	893		—
Finished goods		232		—
	$	1,125	$	—

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of June 30, 2020 are as follows (in thousands):

			Fair Value Measurements Using
			Quoted Prices		Significant
			in Active		Other
	Balance as of		Markets for		Observable
	June 30,		Identical Assets		Inputs
	2020		(Level 1)		(Level 2)
Marketable securities:
US government	$	47,686	$	47,686	$	—
Corporate bonds		44,460		—		44,460
Commercial paper		20,677		—		20,677
Money market funds⁽¹⁾		20,959		20,959		—
Certificates of deposit		2,448		—		2,448
	$	136,230	$	68,645	$	67,585

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2019 are as follows (in thousands):

			Fair Value Measurements Using
			Quoted Prices		Significant
			in Active		Other
	Balance as of		Markets for		Observable
	December 31,		Identical Assets		Inputs
	2019		(Level 1)		(Level 2)
Marketable securities:
US government	$	66,094	$	66,094	$	—
Corporate bonds		68,084		—		68,084
Commercial paper		7,658		—		7,658
Money market funds⁽¹⁾		16,998		16,998		—
Certificates of deposit		4,108		—		4,108
	$	162,942	$	83,092	$	79,850

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The following table summarizes the Company’s marketable securities as of June 30, 2020 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses		Fair Value
Marketable securities:
US government	$	47,152	$	534	$	—	$	47,686
Corporate bonds		44,237		223		—		44,460
Commercial paper		20,676		1		—		20,677
Money market funds⁽¹⁾		20,959		—		—		20,959
Certificates of deposit		2,446		2		—		2,448
	$	135,470	$	760	$	—	$	136,230

⁽¹⁾	Included within cash and cash equivalents on the condensed consolidated balance sheets.

Summary of Fair Values of Marketable Securities by Contractual Maturity

The fair values of marketable securities by contractual maturity consist of the following (in thousands)

	June 30, 2020		December 31, 2019
Maturities within one year	$	109,732	$	114,386
Maturities after one year through three years		26,498		48,556
	$	136,230	$	162,942

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2020

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment, consists of the following as of June 30, 2020 and December 31, 2019 (in thousands):

	June 30, 2020			December 31, 2019
Laboratory equipment	$	307		$	259
Computer equipment and software		855			416
Furniture		597			544
Leasehold improvements		589			530
Manufacturing equipment		226			226
		2,574			1,975
Less: accumulated depreciation and amortization		(1,173	)		(998	)
Property and equipment, net	$	1,401		$	977

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Components of Lease Cost

The components of lease cost for the three and six months ended June 30, 2020 were as follows (in thousands):

	Three Months Ended June 30, 2020			Six Months Ended June 30, 2020
Operating lease cost	$	428		$	858
Sublease income	$	(56	)	$	(112	)
Variable lease cost		30			86
	$	402		$	832

Schedule of Amounts Recognized

The amounts recognized as of June 30, 2020 were as follows (in thousands):

	June 30, 2020
Right of use asset	$	3,011
Long-term lease liability		1,994
Other current liabilities		1,476

Schedule of Supplemental Information Related to Leases

Supplemental information related to leases for the periods reported is as follows (in thousands):

	Six Months Ended June 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		849
Right-of-use assets obtained in exchange for new operating lease liabilities		90
Weighted-average remaining lease term of operating leases	2.55 years
Weighted-average discount rate of operating leases	5.45%

Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis

As of June 30, 2020 undiscounted cash flows to be received under the Company’s operating sublease on an annual basis was as follows (in thousands):

	Operating Leases
Years ending December 31,
Remainder of 2020	$	61
2021		235
2022		243
2023		251
2024		49
2025 and thereafter	—
	$	839

Schedule of Sublease Income Recognized Net within Operating Expenses

Sublease income is recognized net within operating expenses. Sublease income for the three and six months ended June 30, 2020 was as follows (in thousands):

		Three Months Ended June 30, 2020				Six Months Ended June 30, 2020
Sublease income from fixed lease payments		$	56			$	112

Revenue from Product Sales (Tables)

6 Months Ended

Jun. 30, 2020

Revenue From Contract With Customer [Abstract]

Schedule of Net Product Sales

Net product sales consist of the following for the three and six months ended June 30, 2020 (in thousands):

		Three Months Ended June 30, 2020				Six Months Ended June 30, 2020
Jelmyto		$	372			$	372

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations

The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands):

	For the Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Research and development expenses	$	1,570	$	1,972		3,513		4,310
Selling, general and administrative expenses		5,549		5,240		11,223		10,349
	$	7,119	$	7,212	$	14,736	$	14,659

Business and Nature of Operations - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Date of incorporation	2004-04
Date of operating commencement	2016-02

Basis of Presentation - Addititonal Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 297,159	$ 228,017

Significant Accounting Policies - Additional Information (Details) $ in Millions	Jun. 30, 2020 USD ($)
Accounting Policies [Abstract]
Total cash and cash equivalents and marketable securities	$ 151.6

Significant Accounting Policies - Property and Equipment Useful Lives (Details)	6 Months Ended
	Jun. 30, 2020
Computers and Software
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment \| Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment \| Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	6 years 6 months
Furniture \| Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	5 years
Furniture \| Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	16 years 6 months
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	2 years

Other Financial Information - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Other Financial Information [Abstract]
Accounts payable	$ 4,598	$ 4,694
Accrued clinical expenses	409	399
Accrued research and development costs	1,358	2,644
Accrued selling, general and administrative expenses	2,240	2,767
Accrued other expense	598	682
Total accounts payable and accrued expenses	$ 9,203	$ 11,186

Other Financial Information - Schedule of Interest and Other (Income) Expenses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Other Financial Information [Abstract]
Interest income	$ (1,331)	$ (2,353)
Other finance expenses	112	88
Total finance income	$ (1,219)	$ (2,265)

Inventories - Schedule of Inventories (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Inventory Disclosure [Abstract]
Raw materials	$ 893
Finished goods	232
Inventory	$ 1,125

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020 USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, transfers between level 1 to level 2	$ 0
Fair value assets, transfers between level 2 to level 1	0
Fair value liabilities, transfers between level 1 to level 2	0
Fair value liabilities, transfers between level 2 to level 1	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	0
Fair value liabilities, transfers into level 3	0
Fair value liabilities, transfers out of level 3	$ 0

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Marketable securities:
Amortized Cost Basis	$ 135,470
Unrealized Gains	760
Fair Value	136,230	$ 162,942
US Government
Marketable securities:
Amortized Cost Basis	47,152
Unrealized Gains	534
Fair Value	47,686
Corporate Bonds
Marketable securities:
Amortized Cost Basis	44,237
Unrealized Gains	223
Fair Value	44,460
Commercial Paper
Marketable securities:
Amortized Cost Basis	20,676
Unrealized Gains	1
Fair Value	20,677
Money Market Funds
Marketable securities:
Amortized Cost Basis	20,959
Fair Value	20,959
Certificates of Deposit
Marketable securities:
Amortized Cost Basis	2,446
Unrealized Gains	2
Fair Value	$ 2,448

Marketable Securities - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($) Security
Investments Debt And Equity Securities [Abstract]
Accrued interest receivable	$ 500
Available-for-sale debt securities, unrealized gain position	800
Available-for-sale debt securities, unrealized loss position	$ 17,600
Available-for-sale debt securities, number of securities in unrealized loss position \| Security	10
Other-than-temporary impairment Loss, debt securities, portion recognized in earnings	$ 0

Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Available For Sale Securities Debt Maturities Fair Value [Abstract]
Maturities within one year	$ 109,732	$ 114,386
Maturities after one year through three years	26,498	48,556
Debt securities, Available-for-sale	$ 136,230	$ 162,942

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment	$ 2,574	$ 1,975
Less: accumulated depreciation and amortization	(1,173)	(998)
Property and equipment, net	1,401	977
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	307	259
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment	855	416
Furniture
Property Plant And Equipment [Line Items]
Property and equipment	597	544
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	589	530
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment	$ 226	$ 226

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 0.1	$ 0.1	$ 0.2	$ 0.1

Leases - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended	6 Months Ended
Leases - Additional Information (Details) - USD ($)	Nov. 30, 2019	Apr. 30, 2018	Sep. 30, 2017	Jun. 30, 2020	Jun. 30, 2020
Lessee Lease Description [Line Items]
Operating leases, existence of option to extend					true
Operating leases, options to extend lease term, description					UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.
Operating leases, options to extend lease term				3 years	3 years
Operating lease extended lease expiration, month and year					2022-08
Remaining rental payments to be received over the lease term				$ 56,000	$ 112,000
Impairment losses on operating leases					$ 0
Minimum
Lessee Lease Description [Line Items]
Lease expiration year					2021
Maximum
Lessee Lease Description [Line Items]
Lease expiration year					2023
UroGen Pharma Inc. \| New York
Lessee Lease Description [Line Items]
Lease commencement period, month and year			2017-10
Lease termination period, month and year			2021-02
Remaining contractual obligation				500,000	$ 500,000
UroGen Pharma Inc. \| Los Angeles, California
Lessee Lease Description [Line Items]
Lease termination period, month and year		2024-03
Remaining contractual obligation				1,100,000	1,100,000
Lease commencement date		Jul. 10, 2018
Proceeds from tenant allowance		$ 200,000
Lessee operating sublease commencement date	Jan. 01, 2020
Lessee operating sublease termination period, month and year	2024-03
Remaining rental payments to be received over the lease term					800,000
UroGen Pharma Inc. \| Princeton, NJ \| Lease Agreement
Lessee Lease Description [Line Items]
Remaining contractual obligation				$ 1,400,000	$ 1,400,000
Lease commencement date	Nov. 29, 2019
Lease term	38 months

Leases - Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Leases [Abstract]
Operating lease cost	$ 428	$ 858
Sublease income	(56)	(112)
Variable lease cost	30	86
Lease, Cost	$ 402	$ 832

Leases - Schedule of Amounts Recognized (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Right of use asset	$ 3,011	$ 3,735
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent
Long-term lease liability	$ 1,994	$ 2,604
Other current liabilities	$ 1,476
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent

Leases - Schedule of Supplemental Information Related to Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 849
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 90
Weighted-average remaining lease term of operating leases	2 years 6 months 18 days
Weighted-average discount rate of operating leases	5.45%

Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Leases [Abstract]
Remainder of 2020	$ 61
2021	235
2022	243
2023	251
2024	49
Lessee operating sublease payments to be received	$ 839

Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Leases [Abstract]
Sublease income from fixed lease payments	$ 56	$ 112

Revenue from Product Sales - Schedule of Net Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible List]	urgn:JelmytoMember		urgn:JelmytoMember
REVENUES	$ 372	$ 18	$ 372	$ 18

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Nov. 30, 2019	Dec. 31, 2019	Jun. 30, 2020
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payments on license agreement milestone in acquired in process research and development expenses			$ 10,000,000.0
Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000.0
Maximum amount payable upon achieving certain clinical development and regulatory milestones	115,000,000.0
Maximum amount payable upon achieving certain commercial milestones	$ 85,000,000.0
License agreement milestone in acquired in-process research and development expenses		$ 10,000,000.0
Agenus Agreement \| After First Commercial Sale of Licensed Product
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement expiration term	15 years
Maximum \| Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	20.00%
Minimum \| Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	14.00%
Allergan \| License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments received for licensing agreement			25,000,000.0
Allergan \| License Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement additional milestone payments eligible to receive			$ 200,000,000.0

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Dec. 31, 2019	Jan. 31, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Class Of Stock [Line Items]
Ordinary shares, shares authorized	100,000,000		100,000,000	100,000,000
Ordinary shares, issued	21,026,184		22,001,296	22,001,296
Ordinary shares, outstanding	21,026,184		22,001,296	22,001,296
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs			$ 15,777	$ 15,777	$ 161,447
Issuance of ordinary shares, net of issuance expenses				$ 15,885	$ 161,662
Cowen and Company Limited Liability Company \| ATM Sales Agreement
Class Of Stock [Line Items]
Issuance of ordinary shares, shares			700,000
Issuance of ordinary shares, net of issuance expenses			$ 16,600
Net proceeds from issuance ordinary shares after deducting sales commissions			15,800
Issuance of ordinary shares, value, remaining capacity			$ 83,400
Cowen and Company Limited Liability Company \| Maximum \| ATM Sales Agreement
Class Of Stock [Line Items]
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs	$ 100,000
Underwritten Public Offering
Class Of Stock [Line Items]
Issuance of ordinary shares, shares		4,207,317
Additional ordinary shares exercised under underwriters option to purchase at the public offering price		548,780
Issuance of ordinary shares, price per share		$ 41.00
Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs		$ 161,400

Share-Based Compensation - Additional Information (Details)				1 Months Ended				3 Months Ended		6 Months Ended
	Jan. 03, 2019 USD ($) $ / shares shares	Oct. 12, 2018 shares	Jan. 01, 2018 shares	Jun. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($) $ / shares shares	Mar. 31, 2017 shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2019 USD ($) shares	May 31, 2019 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense \| $								$ 7,119,000	$ 7,212,000	$ 14,736,000	$ 14,659,000
Unrecognized compensation cost of options and RSUs \| $				$ 42,300,000				$ 42,300,000		$ 42,300,000
Expected to be recognized over a weighted average period										1 year 9 months 25 days
Options \| General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense \| $					$ 900,000
Options \| Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares	277,432
Exercise price of option to purchase of ordinary shares \| $ / shares	$ 47.57
Options \| Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, expected term				10 years		10 years
Awards vesting period				1 year		1 year
Number of stock options approved for grants				70,000		70,000		70,000	70,000	70,000	70,000
Stock options granted				10,000		10,000
Exercise of option to ordinary shares conversion ratio				1		1
Stock option exercise \| $ / shares				$ 28.24		$ 34.83
Estimated fair value of options granted \| $				$ 1,500,000		$ 1,900,000
Options \| Chairman of Board of Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				10,000		10,000
Options \| Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage										33.00%
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period										2 years
Share-based compensation expense \| $					$ 0
Restricted Stock Units (RSUs) \| Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option to purchase of ordinary shares	317,065
Restricted Stock Units (RSUs) \| Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage										33.00%
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan							1,400,000			5,600,000
Number of ordinary shares reserved for issuance, percentage										12.00%
Increase in number of ordinary share issuable under the 2017 incentive plan		1,900,000	250,167
Stock Options and Restricted Stock Units (RSUs) \| Elizabeth Barrett
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value \| $	$ 24,100,000
Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period										3 years
Combined voting power percentage										10.00%
Ordinary Shares \| 2019 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options approved for grants												900,000
Ordinary Shares \| 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan		3,550,167	1,650,167
Maximum \| Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, expected term										10 years
Minimum \| Plan \| Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as percentage of fair market value of shares on grant date										100.00%
Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power										110.00%

Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 7,119	$ 7,212	$ 14,736	$ 14,659
Research and Development Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	1,570	1,972	3,513	4,310
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 5,549	$ 5,240	$ 11,223	$ 10,349

Commitments and Contingencies - Additional Information (Details) - IIA - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Commitments And Contingent Liabilities [Line Items]
Royalty amount payable		$ 6.6
Maximum percentage of commitment to continue employment of research and development jobs	75.00%
Maximum term for commitment to continue employment of research and development jobs	3 years

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 136,230	$ 162,942
Fair Value, Measurements, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	136,230	162,942
Fair Value, Measurements, Recurring \| US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		66,094
Fair Value, Measurements, Recurring \| Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		68,084
Fair Value, Measurements, Recurring \| Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring \| Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		16,998
Fair Value, Measurements, Recurring \| Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		4,108
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	68,645	83,092
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		66,094
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		16,998
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	67,585	79,850
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		68,084
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		7,658
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:		$ 4,108
Fair Value, Measurements, Recurring \| US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	47,686
Fair Value, Measurements, Recurring \| US Government \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	47,686
Fair Value, Measurements, Recurring \| Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	44,460
Fair Value, Measurements, Recurring \| Corporate Bonds \| Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	44,460
Fair Value, Measurements, Recurring \| Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	20,677
Fair Value, Measurements, Recurring \| Commercial Paper \| Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	20,677
Fair Value, Measurements, Recurring \| Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	20,959
Fair Value, Measurements, Recurring \| Money Market Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	20,959
Fair Value, Measurements, Recurring \| Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	2,448
Fair Value, Measurements, Recurring \| Certificates of Deposit \| Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 2,448